Search Within

Ellen M Hollywood

Formats
  1. Meeting Abstract (23)
  2. Journal Article (17)
  3. Book Section (1)
Groups
  1. Advanced Practice Providers (41)
  2. Nursing (41)
  3. Department of Medicine (37)
  4. Gastrointestinal Oncology Service (37)
  5. Solid Tumor Oncology Division (37)
  6. Center for Pancreatic Cancer Research (28)

More Groups

People
  1. Leonard Saltz (27)
  2. Eileen O'Reilly (15)
  3. Marinela Capanu (14)
  4. Ghassan Abou-Alfa (11)
  5. David Kelsen (9)
  6. James Harding (9)

More People

Years
  1. 2019 (1)
  2. 2018 (4)
  3. 2017 (4)
  4. 2015 (3)
  5. 2014 (3)
  6. 2013 (2)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Clinical Cancer Research (3)
  3. Annals of Oncology (2)
  4. Cancer (2)
  5. European Journal of Cancer (2)
  6. Oncology Nursing Forum (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (3)
  4. Oxford University Press (3)
  5. Oncology Nursing Society (ONS) (2)
  6. Springer (2)

More Publishers

Results (41)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II clinical T trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R) in patients with metastatic well differentiated neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy, D. L.; Hollywood, E.; Segal, M.; Saltz, L.
    Pancreas (2011)

    Fulltext@MSK | Save
  • A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy, D. L.; Hollywood, E.; Segal, M.; Saltz, L.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    Journal Article

    Reidy, D. L.; Vakiani, E.; Fakih, M. G.; Saif, M. W.; Hecht, J. R.; Goodman-Davis, N.; Hollywood, E.; Shia, J. R.; Schwartz, J.; Chandrawansa, K.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study)
    Journal Article

    Zhang, W.; Azuma, M.; Lurje, G.; Gordon, M. A.; Yang, D.; Pohl, A.; Ning, Y.; Bohanes, P.; Gerger, A.; Winder, T.; more...
    Anticancer Research (2010)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)
    Meeting Abstract

    Segal, N. H.; Reidy-Lagunes, D.; Capanu, M.; Kemeny, N.; Chung, K.; Kelsen, D.; Hollywood, E.; Goodman-Davis, N.; Saltz, L. B.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
    Journal Article

    Holen, K.; Saltz, L. B.; Hollywood, E.; Burk, K.; Hanauske, A. R.
    Investigational New Drugs (2008)

    Fulltext@MSK | Save
  • Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    Meeting Abstract

    Zhang, W.; Yang, D.; Capanu, M.; Hollywood, E.; Lue-Yat, M.; Borucka, E.; Azuma, M.; Gordon, M.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5mg/kg can be safely infused over 10 minutes
    Meeting Abstract

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)
    Meeting Abstract

    Azuma, M.; Yang, D.; Carpanu, M.; Hollywood, E.; Lue-Yat, M.; Zhang, W.; Danenberg, K. D.; Danenberg, P. V.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Nursing issues in colorectal cancer chemotherapy
    Book Section

    Hollywood, E.; Semple, D.
    In Saltz, L. B. (Eds.) Colorectal Cancer: Evidence-Based Chemotherapy Strategies (2007)

    Fulltext@MSK | Save